Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

BLUE

Bluebird bio Inc

Jan 17 • 04:00PM ET

8.35

Dollar change +0.09
Percentage change 1.09	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX SRPT BMRN ALNY RGEN IONS SGMO CLLS NTLA EDIT

| Held by: VTI IWM VXF IWN FESM VTWO IWC DFAC VTWV RSSL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-35.97	Insider Own	0.88%	Shs Outstand	9.70M	Perf Week	-1.30%
Market Cap	81.18M	Forward P/E	-	EPS next Y	-8.09	Insider Trans	-31.72%	Shs Float	9.64M	Perf Month	6.91%
Income	-292.83M	PEG	-	EPS next Q	-5.75	Inst Own	34.06%	Short Float	25.04%	Perf Quarter	-13.35%
Sales	53.12M	P/S	1.53	EPS this Y	39.41%	Inst Trans	-29.15%	Short Ratio	5.93	Perf Half Y	-63.70%
Book/sh	-0.60	P/B	-	EPS next Y	62.08%	ROA	-54.29%	Short Interest	2.41M	Perf Year	-70.39%
Cash/sh	7.72	P/C	1.08	EPS next 5Y	-	ROE	-270.20%	52W Range	5.80 - 38.40	Perf YTD	0.12%
Dividend Est.	-	P/FCF	-	EPS past 5Y	28.98%	ROI	-174.36%	52W High	-78.26%	Beta	0.70
Dividend TTM	-	Quick Ratio	0.33	Sales past 5Y	154.57%	Gross Margin	-62.75%	52W Low	43.97%	ATR (14)	0.95
Dividend Ex-Date	-	Current Ratio	0.51	EPS Y/Y TTM	-141.91%	Oper. Margin	-599.54%	RSI (14)	49.23	Volatility	6.36% 11.75%
Employees	375	Debt/Eq	-	Sales Y/Y TTM	144.50%	Profit Margin	-551.26%	Recom	3.20	Target Price	23.98
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	52.30%	Payout	-	Rel Volume	0.27	Prev Close	8.26
Sales Surprise	-41.21%	EPS Surprise	14.87%	Sales Q/Q	-14.36%	Earnings	Nov 14 BMO	Avg Volume	406.86K	Price	8.35
SMA20	-2.04%	SMA50	2.49%	SMA200	-43.03%	Trades		Volume	109,877	Change	1.09%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-15-24	Downgrade	JP Morgan	Neutral → Underweight
Nov-15-24	Downgrade	BofA Securities	Buy → Neutral	$3 → $0.50
Aug-15-24	Downgrade	JP Morgan	Overweight → Neutral
Dec-11-23	Downgrade	HSBC Securities	Hold → Reduce
Dec-08-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$3 → $7
Oct-17-23	Initiated	Cantor Fitzgerald	Neutral
Sep-06-23	Initiated	HSBC Securities	Buy	$4.21
Jul-19-23	Upgrade	BofA Securities	Neutral → Buy	$6 → $10
Jun-01-23	Upgrade	Barclays	Equal Weight → Overweight	$7 → $8
Apr-28-23	Initiated	JP Morgan	Overweight	$7
Mar-07-23	Initiated	Robert W. Baird	Outperform	$10
Aug-05-22	Upgrade	Barclays	Underweight → Equal Weight
Aug-02-22	Upgrade	Raymond James	Mkt Perform → Outperform	$8
Apr-06-22	Downgrade	Cowen	Outperform → Market Perform
Mar-07-22	Downgrade	Barclays	Equal Weight → Underweight	$4
Nov-08-21	Reiterated	Wells Fargo	Equal Weight	$25 → $16
Nov-08-21	Reiterated	Wedbush	Neutral	$22 → $11
Nov-08-21	Reiterated	RBC Capital Mkts	Sector Perform	$26 → $14
Nov-08-21	Reiterated	Canaccord Genuity	Hold	$20 → $15
Nov-08-21	Reiterated	Barclays	Equal Weight	$20 → $13

Show Previous Ratings

Dec-29-24 06:07AM	bluebird bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now? (Insider Monkey)
Dec-08-24 12:30PM	bluebird bio Presents Positive Long-Term Data On LYFGENIA (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition (Business Wire)
Dec-07-24 12:00PM	Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for ß-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels (Business Wire)
Dec-04-24 04:05PM	bluebird bio Announces 1-for-20 Reverse Stock Split (Business Wire) +105.38% -39.73%
08:47AM	bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model (Business Wire)
08:07AM	Loading…
Nov-29-24 08:07AM	FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio's Skysona Gene Therapy (Benzinga) +7.20%
Nov-15-24 02:05PM	JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options (Benzinga) -11.53%
02:07AM	bluebird bio Inc (BLUE) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ... (GuruFocus.com)
Nov-14-24 08:10AM	Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:08AM	Bluebird: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance (Business Wire)
Nov-06-24 04:15PM	bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call (Business Wire) -13.04%
Nov-05-24 09:05AM	bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition (Business Wire)
Oct-31-24 03:48AM	bluebird bio (BLUE): Promising Gene Editing Stock with FDA-Approved Therapies (Insider Monkey) -5.07%
Oct-11-24 09:09AM	Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy (Benzinga)
01:22PM	Loading…
Oct-10-24 01:22PM	Bluebird bios Skysona led to seven cases of blood cancer in gene therapy trials (Pharmaceutical Technology)
Oct-04-24 04:05PM	bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +10.04% -8.67%
Sep-27-24 04:40PM	Bluebird: Q2 Earnings Snapshot (Associated Press Finance)
04:30PM	bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing (Business Wire)
Sep-24-24 12:14PM	Gene Therapy-Focused Bluebird Bio Restructures, Cuts Is Workforce By 25%, Seeks To Breakeven Next Year (Benzinga)
07:00AM	bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025 (Business Wire)
Sep-13-24 05:16PM	Bluebird: Q1 Earnings Snapshot (Associated Press Finance) +5.54%
04:41PM	bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q (Business Wire)
Aug-28-24 09:13AM	FDA will not meet ahead of bluebird bios sickle cell disease gene therapy PDUFA date (Pharmaceutical Technology)
08:00AM	bluebird bio Announces September Investor Events (Business Wire)
Aug-23-24 04:05PM	bluebird bio Announces Receipt of Expected Notices from Nasdaq (Business Wire)
Aug-14-24 07:00AM	bluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance (Business Wire) -23.12%
Aug-12-24 08:00AM	bluebird bio Announces Second Quarter 2024 Results Call Date (Business Wire)
Aug-02-24 04:05PM	bluebird bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -10.81%
Jul-23-24 01:54PM	HHS gives thumbs down to bluebirds fertility support programme (Pharmaceutical Technology) +8.77%
04:05PM	Loading…
Jul-03-24 04:05PM	bluebird bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-17-24 03:27PM	7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline (InvestorPlace)
Jun-02-24 10:15PM	2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner (PR Newswire)
May-29-24 07:00AM	bluebird bio Appoints O. James Sterling as Chief Financial Officer (Business Wire)
May-17-24 03:46PM	BLUE vs. CRSP: Why Are These Stocks Moving in Opposite Directions? (TipRanks)
May-16-24 09:22AM	Is Bluebird Bio Stock a Buy? (Motley Fool)
May-14-24 11:24AM	Shareholders of bluebird bio, Inc. Should Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights BLUE (GlobeNewswire)
May-10-24 03:36PM	bluebird bio Inc (BLUE) Q1 2024 Earnings: Surpasses Revenue Expectations with Strategic Focus ... (GuruFocus.com) -5.36%
01:34PM	bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well (Zacks)
May-09-24 07:00AM	bluebird bio Reports First Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance (Business Wire) +14.92%
May-07-24 12:40PM	bluebird bio, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights BLUE (GlobeNewswire)
May-06-24 07:05AM	bluebird bio Announces First Quarter 2024 Results Call Date and Upcoming Investor Events (Business Wire) +11.14%
07:00AM	bluebird bio Announces Completion of First Cell Collection for LYFGENIA Gene Therapy (Business Wire)
Apr-26-24 04:43PM	bluebird bio Gets Nasdaq Notice for Late Filing of Annual Report (MT Newswires)
04:05PM	bluebird bio Announces Receipt of Expected Notice from Nasdaq (Business Wire)
Apr-16-24 02:05PM	bluebird (BLUE) Underperforms Industry YTD Amid Challenges (Zacks)
Apr-15-24 08:15AM	Is Bluebird Bio Stock a Buy? (Motley Fool) -6.36%
Apr-13-24 04:22PM	Better Buy: Bluebird Bio Vs. Novavax (Motley Fool)
Apr-11-24 08:30AM	Is This Beaten-Down Stock a Good Acquisition Target? (Motley Fool)
08:00AM	bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-02-24 11:33AM	bluebird bio, Inc. (NASDAQ:BLUE) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-29-24 05:20AM	Bluebird Bio Stock Has 138% Upside, According to 1 Wall Street Analyst (Motley Fool)
Mar-27-24 11:37AM	bluebird (BLUE) Misses on Q4 Revenues, Provides Portfolio Updates (Zacks) +13.75%
10:00AM	Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline (Zacks)
Mar-26-24 07:01AM	bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance (Business Wire) -11.76%
Mar-25-24 04:05PM	bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call (Business Wire)
Mar-19-24 07:44AM	bluebird (BLUE) Gets $175 Million Loan From Hercules, Shares Up (Zacks)
Mar-18-24 06:05PM	Why Bluebird Bio Stock Flew Higher Than the Market Today (Motley Fool)
08:00AM	bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital (Business Wire)
Mar-13-24 07:50AM	Is Bluebird Bio Stock a Buy Now? (Motley Fool)
Mar-11-24 08:00AM	bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy (Business Wire) -7.33%
Mar-05-24 06:56PM	Why Bluebird Bio Stock Dived Into the Red on Tuesday (Motley Fool) -9.15%
Jan-27-24 07:28AM	If You Invested $1,000 in Bluebird Bio in 2019, This Is How Much You Would Have Today (Motley Fool)
05:27AM	5 Best 52-Week Low Stocks To Buy Now (Insider Monkey)
Jan-10-24 06:55AM	2 Red Flags for Bluebird Bio Stock (Motley Fool)
Jan-08-24 08:00AM	bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook (Business Wire)
Jan-04-24 03:32PM	Bluebirds Plans to Win in Sickle Cell Come Into Focus (The Wall Street Journal) +5.84%
Jan-03-24 07:15AM	Better Risky Investment: Bluebird Bio vs. Shiba Inu (Motley Fool) -6.80%
Jan-02-24 08:00AM	bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +6.52%
Dec-26-23 08:00AM	Should You Invest in Bluebird Bio Right Now? (Motley Fool)
Dec-24-23 07:39AM	If You Invested $10,000 in Bluebird Bio In 2021, This Is How Much You Would Have Today (Motley Fool)
Dec-23-23 07:30AM	1 Green Flag and 1 Red Flag for Bluebird Bio Stock (Motley Fool)
Dec-22-23 08:45AM	3 Money-Saving Tricks for Investing in Biotech Stocks in 2024 (Motley Fool)
Dec-20-23 02:23PM	Bluebird Bio Stock Plunges (Barrons.com) -45.68%
01:54PM	Bluebird Bio Stock Is in Free Fall Weeks After a Landmark FDA Approval. Heres Why. (Barrons.com)
Dec-19-23 09:41PM	bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock (Business Wire) -20.33%
Dec-18-23 04:01PM	bluebird bio, Inc. Announces Proposed Public Offering of Common Stock (Business Wire) -6.73%
Dec-15-23 11:14AM	Down 30% in a Week, What in the World Is Going On With Bluebird Bio Stock? (Motley Fool)
Dec-11-23 05:43AM	Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug? (Motley Fool) +7.34%
Dec-10-23 12:02PM	Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels (Business Wire)
Dec-09-23 11:31AM	Long-term Follow-up Data From bluebirds Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events (Business Wire)
Dec-08-23 01:45PM	FDA Approves Worlds First Crispr Gene-Editing Drug for Sickle-Cell Disease (The Wall Street Journal) -40.54%
01:01PM	bluebird bio Details Plans for the Commercial Launch of LYFGENIA Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events (Business Wire)
12:35PM	bluebird bio Announces FDA Approval of LYFGENIA (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events (Business Wire)
Dec-07-23 11:30AM	Bluebird (BLUE) Up 48.2% Since Last Earnings Report: Can It Continue? (Zacks)
08:45AM	These 2 Stocks Could Be About to Soar: Are They Buys? (Motley Fool)
Dec-01-23 07:41AM	bluebird bio (BLUE) Stock Gains 25.6% in a Month: Here's How (Zacks) +11.52%
Nov-29-23 02:28PM	If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names (InvestorPlace)
Nov-26-23 04:44PM	2 Biotech Stocks That Could Soar in December (Motley Fool)
Nov-24-23 07:00AM	Gene Editing Will Change Medicineand Maybe Health Investing Too (The Wall Street Journal)
Nov-08-23 03:39PM	bluebird bio, Inc. (NASDAQ:BLUE) Q3 2023 Earnings Call Transcript (Insider Monkey) -7.91%
Nov-07-23 05:18PM	Why Bluebird Bio Stock Soared 7% Higher on Tuesday (Motley Fool) +7.27%
08:00AM	Bluebird Bio Inc (BLUE) Reports Q3 2023 Financial Results: Strong Commercial Launch and ... (GuruFocus.com)
07:46AM	Bluebird Bio Q3 Loss Narrows, Tops Estimates; Revenues Miss Estimates (RTT News)
07:27AM	Bluebird: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress (Business Wire)
Nov-04-23 08:45AM	Is Bluebird Bio Stock a Buy? (Motley Fool)
Nov-02-23 09:37AM	bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition (Business Wire)
Oct-30-23 08:00AM	bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million (Business Wire)
Oct-24-23 08:00AM	bluebird bio to Host Third Quarter 2023 Financial Results Conference Call (Business Wire)

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Colvin Richard A	Chief Medical Officer	Jan 06 '25	Sale	9.24	19	176	8,257	Jan 08 04:06 PM
Obenshain Andrew	President and CEO	Jan 06 '25	Sale	9.24	140	1,294	18,571	Jan 08 04:06 PM
Colvin Richard A	Officer	Jan 06 '25	Proposed Sale	8.74	19	166		Jan 07 05:31 PM
Obenshain Andrew	Officer	Jan 06 '25	Proposed Sale	8.74	140	1,223		Jan 06 06:23 PM
Obenshain Andrew	President and CEO	Dec 10 '24	Sale	0.42	971	405	374,247	Dec 12 04:01 PM
Colvin Richard A	Chief Medical Officer	Dec 10 '24	Sale	0.42	2,824	1,178	165,544	Dec 12 04:01 PM
Colvin Richard A	Officer	Dec 10 '24	Proposed Sale	0.45	2,824	1,271		Dec 10 09:51 PM
Obenshain Andrew	Officer	Dec 10 '24	Proposed Sale	0.45	971	437		Dec 10 09:39 PM
Klima Thomas J	See Remarks	Sep 30 '24	Sale	0.53	1,006	529	170,000	Oct 02 04:06 PM
Obenshain Andrew	President and CEO	Sep 30 '24	Sale	0.53	34,780	18,270	375,218	Oct 02 04:06 PM
Obenshain Andrew	Officer	Sep 30 '24	Proposed Sale	0.52	34,780	18,086		Oct 01 03:10 PM
Klima Thomas J	Officer	Sep 30 '24	Proposed Sale	0.52	1,006	523		Oct 01 01:33 PM
Klima Thomas J	See Remarks	Jun 03 '24	Sale	0.97	3,834	3,726	121,006	Jun 04 04:22 PM
Colvin Richard A	Chief Medical Officer	Mar 01 '24	Sale	1.53	6,770	10,342	118,368	Mar 05 05:40 PM
Obenshain Andrew	President and CEO	Mar 04 '24	Sale	1.53	6,095	9,311	279,998	Mar 05 05:40 PM
Klima Thomas J	See Remarks	Mar 04 '24	Sale	1.53	4,573	6,986	124,840	Mar 05 05:39 PM
Klima Thomas J	See Remarks	Feb 05 '24	Sale	0.90	2,714	2,449	129,413	Feb 06 04:07 PM
Vittiglio Joseph	Chief Business & Legal Officer	Feb 05 '24	Sale	0.90	5,217	4,708	44,783	Feb 06 04:07 PM
Obenshain Andrew	President and CEO	Feb 05 '24	Sale	0.90	1,879	1,696	286,093	Feb 06 04:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BLUE

Bluebird bio Inc

Upgrade your FINVIZ experience